Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LIG1
REST API REST API
Homo sapiens
LIG1 is differentially expressed in 256 experiments: 102 organism parts: bone marrow, spleen, ... (100 more);, 187 disease states: normal, acute lymphoblastic leukemia, ... (185 more);, 86 cell types 260 cell lines 33 compound treatments and 71 other conditions.
Orthologs LIG1 (Gallus gallus)   Lig1 (Rattus norvegicus)   Lig1 (Mus musculus)   A4IFC8_BOVIN (Bos taurus)   CDC9 (Saccharomyces cerevisiae)   F6Y1Y0_CIOIN (Ciona intestinalis)   LIG1 (Danio rerio)   lig1 (Xenopus laevis)   LIG1 (Canis familiaris)   DNA-ligI (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term ligase activity, telomere maintenance, cell division, DNA binding, double-strand break repair via homologous recombination, nucleotide-excision repair, DNA ligase (ATP) activity, DNA repair, mitotic cell cycle, metal ion binding, double-strand break repair, ATP binding, anatomical structure morphogenesis, telomere maintenance via recombination, nucleus, DNA recombination, nucleotide binding, nucleoplasm, base-excision repair, S phase of mitotic cell cycle, DNA replication, DNA strand elongation involved in DNA replication, DNA metabolic process, nucleotide-excision repair, DNA gap filling, transcription-coupled nucleotide-excision repair, DNA ligation involved in DNA repair, DNA ligation, DNA ligase activity, telomere maintenance via semi-conservative replication
InterPro Term DNA_ligase_ATP-dep_cent, DNA_ligase_ATP-dep_C, DNA_ligase_ATP-dep_N, DNA_ligase_ATP-dep
UniProt Accession P18858, Q76GR4, B4DTU4, F5GZ28, B4E135
Search EB-eye ENSG00000105486
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
Jurkat
2
E-GEOD-1880, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-GEOD-18005
U87
2
E-MEXP-903, E-GEOD-20089
ITM-E6E7
1
E-GEOD-2487
254 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
plasma cell
2
E-GEOD-6691, E-MEXP-2360
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-MEXP-1600
adipocyte
1
2
E-AFMX-5, E-TABM-145, E-MTAB-25
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (55 experiments)

Factor Value U/D Experiments
retinoblastoma
2
E-GEOD-96, E-MTAB-37
lung adenocarcinoma
2
E-MEXP-231, E-MTAB-37
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MEXP-1331, E-MTAB-62
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
181 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-2649, E-GEOD-995, E-GEOD-2803, E-GEOD-6907, ... (7 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
hydroxyurea
1
E-GEOD-6431
TNF
1
E-GEOD-15205
4OH-tamoxifen
1
E-GEOD-2292
M-CSF
1
E-GEOD-5099
27 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-20499, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-19665

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-GEOD-17385, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-3494, E-GEOD-2466, E-MEXP-421, E-GEOD-18736, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-GEOD-16363, ... (28 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21574

Stimulation
studied in E-GEOD-11886

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.302 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM